Genetic Association between Gene Polymorphisms and Risk of Prostate Cancer: A Meta-Analysis.

Studies suggests that ()-1306 C/T and -1607 1G/2G polymorphisms affect the risk of prostate cancer. However, the conclusions remain controversial and no pooled evidence of this topic has been published. Therefore, we aimed to perform a meta-analysis to shed some light on the controversial conclusion pertaining to the associations of -1306 C/T and -1607 1G/2G polymorphisms with prostate cancer susceptibility. A thorough literature search was performed up to August, 2016 with the PubMed, EMBASE, CBM, CNKI, and Wanfang databases. Odds ratios (ORs) and corresponding 95% confidence intervals (95% CIs) were calculated to address the correlations between these polymorphisms and risk of prostate cancer. The meta-analysis included six studies (1,921 patients and 1,988 controls) on -1306 C/T polymorphism and three studies on -1607 1G/2G polymorphism (438 patients and 394 controls), respectively. The overall results of meta-analysis showed that an elevated risk of the disease was implicated in -1306 C/T polymorphism under two genetic models (CT vs. CC: OR = 1.78, 95% CI = 1.33-2.38; TT+CT vs. CC: OR = 1.62, 95% CI = 1.24-2.12) and no significant association was observed between -1607 1G/2G polymorphism and the risk of prostate cancer. The subgroup analysis results of -1306 C/T polymorphism were similar to the overall results. However, decreased risk of prostate cancer was observed in the Caucasians for -1607 1G/2G polymorphism. Current meta-analysis indicates that -1306 C/T polymorphism is associated with elevated risk of prostate cancer, but -1607 1G/2G polymorphism may inhibit the occurrence of prostate cancer in Caucasians. Further studies are warranted to verify the conclusions.